Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05380492
PHASE1/PHASE2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Sponsor: Perceive Biotherapeutics, Inc.

View on ClinicalTrials.gov

Summary

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Official title: Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2022-11-17

Completion Date

2025-11

Last Updated

2024-04-11

Healthy Volunteers

No

Interventions

BIOLOGICAL

VOY-101

Intravitreal injection of VOY-101

Locations (3)

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Retina Consultants of Texas

Bellaire, Texas, United States

University of Utah

Salt Lake City, Utah, United States